TAKEDA TAK-620-2004 SUBJECT

A Phase 3, open-label, single-arm, repeated-dose study to evaluate the safety and tolerability, pharmacokinetics, and antiviral activity of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT). This app allows participants in the clinical trial to enter their daily diaries and communicate directly with research sites and coordinators.